leisure time -WSS

leisure time

author：knowledge 2025-09-29 00:34:11 - browse：3139

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Brazil's Jair Bolsonaro is barred from running for office until 2030

Wikipedia

WSS

Syphilis numbers in the United States reach record heights

Why you shouldn’t ask, “What country has the best health care?”

Wegovy leads to weight loss. Can it treat depression, too?

GOP inquiry over gain

Why you shouldn’t ask, “What country has the best health care?”

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

leisure time

leisure time

leisure time

Heart attack and stroke risk calculators need revising

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Medical leaders decry Supreme Court decision on affirmative action

Wegovy leads to weight loss. Can it treat depression, too?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Synthetic human embryos? Researchers say term is overblown

Medical records are filled with copy

Why you shouldn’t ask, “What country has the best health care?”

The high cost of giving birth even with insurance

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

hotspot

Biogen walks away from Aduhelm, years after polarizing approval

Boston competes with Raleigh

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Zyn nicotine pouches become unlikely player in latest culture war

FTC sues over Novant Health acquisition of two N.C. hospitals

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

focus

Wikipedia

hotspot

explore